Xintong Shen

Objectives To construct a nomogram model for predicting the danger of fear of cancer recurrence in postoperative cervical cancer patients and to verify the predictive efficacy of the model. Methods A total of 310 patients who underwent cervical cancer surgery at the Gynecologic Oncology Department of the First Affiliated Hospital of Bengbu Medical University from May 2024 to December 2024. The influencing factors were screened using single and multifactor stepwise logistic regression analysis. A nomogram prediction model was built using these predictors. Using 1,000 bootstrap resamples and the area under the curve(AUC) of the participants’ operating characteristics, the model’s effectiveness was confirmed. Results Within the study population, 174 out of 310 patients(56.12%)exhibited a fear of cancer recurrence. Multifactorial analysis highlighted that variables such as age, educational level, treatment modality, Social Support Rate Scale(SSRS), and monthly family income significantly influenced fear of cancer recurrence in patients with postoperative cervical cancer( P < 0.05). Subsequently, a predictive model was established based on these factors. The model’s goodness-of-fit was assessed using the Hosmer-Lemeshow test, yielding a χ ² value of 6.773( P = 0.610). The area under the receiver operating characteristic curve(AUC) was determined to be 0.910(95%CI 0.853-0.966), with a sensitivity of 87.5% and specificity of 81.2%. Conclusion The research results indicate that the incidence of fear of cancer recurrence is high among them. Furthermore, the developed prediction model’s high predictive efficacy, suggesting its potential utility for individualized risk assessment concerning fear of cancer recurrence in this patient population. This model was developed and validated in a single-center cohort, and its generalizability requires future external validation.

F1012-2, a novel sesquiterpene lactone isolated from the Chinese herbal medicine Eupatorium lindleyanum DC, exhibits an antitumor effect. In this study, we investigated the anticancer activities of F1012-2 on ten human breast cancer lines and demonstrated significantly lower IC50 values for triple-negative breast cancer (TNBC) than for non-TNBC cell lines. The transcription factors p53 and nuclear factor-?B (NF-?B) are important regulators of tumorigenesis. F1012-2 not only depleted mutant p53, but also activated wild-type p53. F1012-2 reduced the expression of phosphorylated p65 and p105 NF-?B family members and coregulated p53, NF-?B members and their dependent targets. To further clarify the key role of p53, lentivirus small hairpin RNA (shRNA) infection was used to knockdown p53 in MDA-MB-231 cells. F1012-2 significantly reduced the inhibitory effect on cell proliferation and apoptosis, while the levels of p53, NF-?B family members and their dependent genes were not significantly different. F1012-2 exhibited a significant antitumor effect and reduced the expression of p53 in MDA-MB-231 xenografts. Taken together, our results show that F1012-2 exhibited an inhibitory effect on TNBC and affected the regulation of p53/NF-?B signaling pathways.

Objective: This study employed computational pharmacology to explore the possible therapeutic targets and molecular mechanisms of F1012-2, a novel sesquiterpene lactone from Eupatorium lindleyanum DC. (EL), against viral pneumonia. Methods: With network pharmacology, we first looked into various databases for genes and proteins related to viral pneumonia, as well as the potential targets of F1012-2. By overlapping these 2 groups of genes, we acquired the candidate targets of F1012-2 against viral pneumonia. Afterward, enrichment analysis was performed to elucidate the interactive targets in the Database for Annotation, Visualization and Integrated Discovery (DAVID) database. The protein–protein interaction (PPI) network was constructed through the STRING database, and the results were imported into Cytoscape software to search for the key genes by Network Analyzer. Finally, molecular docking analysis was used to further validate the candidate targets of F1012-2 against viral pneumonia. Results: A total of 110 target genes were found for the 3 compounds within F1012-2 (Eupalinolide G, [EG] Eupalinolide I, [EI] and Eupalinolide J [EJ]), while 4322 potential therapeutic targets were uncovered related to viral pneumonia, and the intersection of the 2 groups generated 78 target genes. Among the candidate genes, epidermal growth factor receptor (EGFR), interleukin-1beta (IL1B), tyrosine-protein kinase SRC, Caspase-3 (CASP3), and transcription factor and oncoprotein JUN have the highest degree, betweenness, and closeness, which could fit into binding with EG, EI, and EJ. The enrichment analysis indicated that the major pathways involved were sphingolipid, neurotrophin, tumor necrosis factor (TNF), and Toll-like receptor signaling pathways. Conclusion: These findings showed that by the combination of network pharmacology and molecular docking, we could speculate on the possible mechanism of F1012-2's effect on viral pneumonia, with EGFR, IL1B, SRC, and CASP3 as the promising targets.